Search

Author/Creator Cavo, M.

1. 98 CLINICAL RESPONSE TO THE ASSOCIATION OF AZACITIDINE AND LENALIDOMIDE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES. A RANDOMIZED PHASE II MULTICENTER STUDY. Issue 1 (April 2015)

Authors:
Finelli, C.; Clissa, C.; Follo, M.Y.; Stanzani, M.; Parisi, S.; Avanzini, P.; Bosi, C.; Castagnari, B.; Candoni, A.; Crugnola, M.; Giannini, M.B.; Gobbi, M.; Leonardi, G.; Rigolin, G.M.; Russo, D.; Tosi, P.; Visani, G.; Cocco, L.; Cavo, M.
Journal:
Leukemia research
Issue:
Volume 39:Issue 1(2015:Jan.)
Page Start:
S50
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Addition of Lenalidomide to Azacitidine in Higher Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study. (April 2017)

Authors:
Finelli, C.; Clissa, C.; Follo, M.; Barraco, M.; Mongiorgi, S.; Avanzini, P.; Bosi, C.; Castagnari, B.; Candoni, A.; Crugnola, M.; Giannini, M.B.; Gobbi, M.; Leonardi, G.; Rigolin, G.M.; Russo, D.; Tosi, P.; Pellagatti, A.; Boultwood, J.; Cocco, L.; Cavo, M.
Journal:
Leukemia research
Issue:
Volume 55(2017)Supplement 1
Page Start:
S50
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME. (23rd June 2022)

Authors:
Palandri, F.; Bartoletti, D.; Breccia, M.; Auteri, G.; Elli, E. M.; Trawinska, M. M.; Polverelli, N.; Tiribelli, M.; Benevolo, G.; Iurlo, A.; Tieghi, A.; Heidel, F. H.; Caocci, G.; Beggiato, E.; Binotto, G.; Cavazzini, F.; Miglino, M.; Bosi, C.; Crugnola, M.; Bocchia, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
900
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB. (23rd June 2022)

Authors:
Palandri, F.; Bartoletti, D.; Elli, E. M.; Auteri, G.; Bonifacio, M.; Benevolo, G.; Heidel, F.; Trawinska, M. M.; Rossi, E.; Bosi, C.; Tieghi, A.; Tiribelli, M.; Iurlo, A.; Polverelli, N.; Caocci, G.; Binotto, G.; Cavazzini, F.; Beggiato, E.; Cilloni, D.; Tatarelli, C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
901
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P342: BASELINE GENE EXPRESSION ANALYSIS OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH INOTUZUMAB OZOGAMICIN. (23rd June 2022)

Authors:
Sartor, C.; Vigliotta, I.; Robustelli, V.; Cristiano, G.; Nanni, J.; Zannoni, L.; Parisi, S.; Paolini, S.; Marconi, G.; Martinelli, G.; Curti, A.; Cavo, M.; Terragna, C.; Papayannidis, C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
242
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY. (23rd June 2022)

Authors:
Castagnetti, F.; Bocchia, M.; Abruzzese, E.; Capodanno, I.; Bonifacio, M.; Rege Cambrin, G.; Crugnola, M.; Binotto, G.; Elena, C.; Lucchesi, A.; Bergamaschi, M.; Albano, F.; Luciano, L.; Sorà, F.; Lunghi, F.; Stagno, F.; Cerrano, M.; Iurlo, A.; Scortechini, A. R.; Leonetti Crescenzi, S.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
593
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗